46155-89-9

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione is used as a building block for the synthesis of various pharmaceutical drugs and biologically active compounds due to its versatile chemical structure and potential pharmacological properties.
Used in Drug Development:
1,3-Dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione is used as a subject of research in drug development for its potential applications in the creation of new pharmaceutical drugs and biologically active compounds.
Used in Medicinal Chemistry:
1,3-Dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione is used in the field of medicinal chemistry for its reported anti-cancer and anti-inflammatory activities, making it a promising candidate for further research and development.
Used in Cancer Research:
1,3-Dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione is used as a subject of research in cancer research for its potential anti-cancer properties, with the aim of developing new therapeutic agents for cancer treatment.
Used in Inflammation Research:
1,3-Dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione is used as a subject of research in inflammation research for its potential anti-inflammatory properties, with the aim of developing new therapeutic agents for the treatment of inflammatory diseases.

InChI:InChI=1/C8H9N3O2/c1-10-5-3-4-9-6(5)7(12)11(2)8(10)13/h3-4,9H,1-2H3

Upstream product

• 55276-27-2 1,3-dimethyl-6-<2-(dimethylamino)vinyl>-5-nitrouracil 
• 116705-30-7 1,3-dimethyl-6-(2-dimethylaminovinyl)-5-nitrouracil 
• 61541-41-1 6-azido-1,3-dimethylpyrimidine-2,4(1H,3H)-dione 
• 1560-54-9 allyltriphenylphosphonium bromide 
• 13509-52-9 1,3,6-trimethyluracil 
• 303768-04-9 C₁₂H₁₆N₄O₅ 
• 19674-60-3 3,6-dimethyluracil 
• 55326-07-3 1,3,6-trimethyl-5-nitrouracil 

Downstream Products

• 1366000-21-6 N-(3,4-difluoro-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-22-7 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-trifluoromethyl-phenyl)-acetamide 
• 1366000-23-8 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-trifluoromethoxy-phenyl)-acetamide 
• 1366000-24-9 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-trifluoromethylsulfanyl-phenyl)-acetamide 
• 1366000-25-0 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-methoxy-phenyl)-acetamide 
• 1366000-26-1 N-(4-diethylsulfamoyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-27-2 N-(4-benzylsulfamoyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-28-3 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-isopropyl-phenyl)-acetamide 
• 1366000-29-4 N-(4-tert-butyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-30-7 N-(4-butyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-31-8 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-hexyl-phenyl)-acetamide 
• 1366000-32-9 N-(4-cyclohexyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-33-0 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-morpholin-4-yl-phenyl)-acetamide 
• 1366000-35-2 N-benzyl-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 

Relevant academic research and scientific papers

Pyrrolopyrimidines. 1. Electrophilic Substitution Reactions of 1,3-Dimethylpyrrolopyrimidine-2,4-dione

The reactions of halogenation, aminomethylation, acylation, and azo coupling in 1,3-dimethylpyrrolopyrimidine-2,4-dione proceed at position 7, whereas nitration in acetic acid is direct primarily to position 6.In a number of cases, products of subs

7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation

The transient receptor potential ankyrin 1 (TRPA1) channel is activated by a series of by-products of oxidative/nitrative stress, produced under inflammatory conditions or in the case of tissue damage, thus generating inflammatory and neuropathic pain and

FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl. Formula (I)

A facile synthesis of pyrrolo-[3,2-d]pyrimidines from 6-azidouracils and ylide phosphoranes

A series of the title compounds, 9-deazaxanthines, was regioselectively prepared in reasonable yields as major products from the reactions of 6-azidouracils 1a,b with stabilized ester-2a,b or keto-2c ylide phosphoranes and a moderated phosphorus ylide 3, instead of the expected triazoles. Side products were also observed wherein pyrimido[5,4-g]pteridine-2,4,5,7-tetrone (15) and other fused ring systems or acyclic-substituted uracil derivatives were isolated. A comparative study on the reactivity of 1a in analogy to 1b toward phosphoranes is also described.

Pyrrolopyrimidines. 4. A convenient method for the production of 6-(2-aminovinyl)-5-nitropyrimidines and their transformation into pyrrolo[3,2-d]pyrimidines

A convenient method is proposed for the production of 6-(2- aminovinyl)pyrimidine-2,4-diones, involving the reaction of 6-methyluracils with triethyl orthoformiate and secondary amines.

Synthesis and structure-activity relationships of deazaxanthines: Analogs of potent A1- and A2-adenosine receptor antagonists

A set of 22 9-deazaxanthines (pyrrolo[3,2-d]pyrimidine-2,4-diones) and three 7-deazaxanthines (pyrrolo[2,3-d]pyrimidine-2,4-diones) with various substituents in the 1-, 3-, 7- or 9-, and 8-positions was synthesized and investigated in A1 and A2a adenosine receptor binding assays at rat brain cortical membranes and rat brain striatal membranes, respectively. 9- Deazaxanthines showed structure-activity relationships that were similar to those of xanthines. They were about equipotent to the corresponding xanthines at A2a adenosine receptors. 9-Deazaxanthines were generally at least 1-3- fold more potent than xanthines at A1 receptors and therefore exhibited higher A1 selectivities compared to the xanthines. 1,3-Dimethyl-8-(2- naphthyl)-9-deazaxanthine (19e) showed high affinity (K(i) = 26 nM) and selectivity for A1 adenosine receptors. A hydroxyl function at N7 of 9- deazaxanthines was unfavorable for A1 and A2a receptor binding. 7- Deazaxanthines were considerably less potent compared to xanthines and to 9- deazaxanthines at both receptor subtypes.